A major shift in approach is needed if patient-reported adverse events are to enable clearer safety insights and better safety outcomes.
Simply throwing AI at dispersed and incomplete safety data cannot achieve that. Progress starts with better data capture, and that requires a stronger mandate and guided digital experiences for those tasked with collecting it.
The ambitions of patient safety and ongoing pharmacovigilance are very clear – making drugs and therapies as safe as they can be so that they deliver ever better outcomes. Yet this entire endeavour is threatened by the enormous complexity in capturing meaningful, high-quality insights and acting on them swiftly.
Check out the rest of the feature here
